SOLV Stock Forecast: Solventum Corp. Price Predictions for 2026-2027
The 15 Wall Street analysts covering Solventum Corp. hold a median 12-month price target of $100 — +18.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 76 of 100 as at 21 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Solventum Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (89): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Growth (34): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
SOLV stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on SOLV, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +18.3% from it.
Of the 20 most recent actions, 8 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 6 Nov 2026 | Piper Sandler | Reiterates | Overweight | $105 → $110 |
| 6 Nov 2026 | Wells Fargo | Maintains | Equal-Weight | $89 → $95 |
| 14 Sept 2026 | BTIG | Reiterates | Buy | $95 |
| 6 Aug 2026 | BTIG | Maintains | Buy | $91 → $95 |
| 6 Aug 2026 | Keybanc | Maintains | Overweight | $93 → $102 |
| 6 Aug 2026 | Piper Sandler | Maintains | Overweight | $92 → $105 |
| 6 Aug 2026 | Stifel | Maintains | Buy | $90 → $100 |
| 6 Aug 2026 | UBS | Maintains | Buy | $95 → $101 |
| 6 Aug 2026 | Wedbush | Maintains | Outperform | $94 → $101 |
| 28 July 2026 | UBS | Upgrade | Buy | $95 |
| 9 July 2026 | BMO Capital | Initiates | Market Perform | — |
| 15 May 2026 | Wedbush | Initiates | Outperform | — |
| 6 May 2026 | BTIG | Reiterates | Buy | — |
| 6 May 2026 | Keybanc | Maintains | Overweight | — |
| 6 May 2026 | Stifel | Maintains | Buy | — |
| 6 May 2026 | UBS | Maintains | Neutral | — |
| 6 May 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 27 Apr 2026 | Keybanc | Maintains | Overweight | — |
| 17 Apr 2026 | Piper Sandler | Maintains | Overweight | — |
| 24 Mar 2026 | Rothschild & Co | Initiates | Sell | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for SOLV.
This page is one stock. Monday covers all of them.
SOLV appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
SOLV vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Solventum Corp. returned +6.3% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
SOLV analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 94.9×
- Price / sales
- 1.8×
- Price / book
- 3.0×
- EV / EBITDA
- 19.1×
Cheaper than 9% of US stocks
Cheaper than 52% of US stocks
Cheaper than 31% of US stocks
Cheaper than 22% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- 58.2%
- Operating margin
- 5.9%
- Net margin
- —
Higher than 71% of US stocks
Higher than 56% of US stocks
- Return on equity
- 3.2%
- Return on assets
- 2.1%
- Dividend yield
- —
Higher than 49% of US stocks
Higher than 59% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Solventum Corp. has a market value of $14.4B and an enterprise value of $19.2B.
Revenue in the twelve months to 30 June 2026: $8.3B. The latest quarter grew 2.2% year on year.
Net income over the same four quarters: $1.4B, a 17.3% net margin.
Diluted earnings per share, trailing twelve months: $8.18.
Free cash flow in the twelve months to 30 June 2026: −$118.0M.
Trailing P/E: 94.9×; forward P/E: 11.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Solventum Corp. employs 20,584 people — $404K of revenue per employee.
Data provided by Twelve Data
SOLV and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at SOLV’s peer groups, ranked by the model: healthcare stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Solventum Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about SOLV
What is the SOLV stock price forecast for 2026-2027?
The 15 Wall Street analysts covering Solventum Corp. have a median 12-month price target of $100, with estimates ranging from $75 to $115. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is SOLV stock a buy right now?
Of the 15 analysts covering Solventum Corp., 8 rate it a Buy, 5 a Hold and 2 a Sell. Ticker Nerd's systematic factor model ranks Solventum Corp. 76 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank SOLV?
As at 21 Nov 2026, Solventum Corp. ranks 76 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Value (89 of 100).
Will SOLV stock go up?
No one can know that. What the data says: the median 12-month target from 15 analysts implies +18.3% from the last close, and Ticker Nerd's factor model ranks Solventum Corp. 76 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the SOLV stock forecast for 2030?
No analyst covering Solventum Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SOLV are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $75 to $115 over the next 12 months.
How has SOLV stock performed over the past year?
Solventum Corp. returned +6.3% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Solventum Corp. do?
Solventum Corporation is a healthcare company that develops and commercializes a broad portfolio of products and software designed to address clinical and operational needs across care settings. Its Medsurg business provides wound care, skin care, I.V. site management, sterilization assurance, temperature management, surgical supplies, medical tapes and wraps, stethoscopes, and medical electrodes.
About Solventum Corp.
Solventum Corporation is a healthcare company that develops and commercializes a broad portfolio of products and software designed to address clinical and operational needs across care settings. Its Medsurg business provides wound care, skin care, I.V. site management, sterilization assurance, temperature management, surgical supplies, medical tapes and wraps, stethoscopes, and medical electrodes. The Dental Solutions segment offers products used in restorative and orthodontic workflows, including brackets, aligners, cements, and bonding agents. Through Health Information Systems, Solventum supplies software and services that support physician documentation, coding automation, speech recognition, and data visualization for healthcare organizations. The company serves customers in the United States and internationally through direct sales, distribution, key account management, inside sales, and e-commerce. Headquartered in Eagan, Minnesota, Solventum focuses on technologies that support safer, more efficient healthcare delivery.
CEO Mr. Bryan C. Hanson · 20,584 employees · United States · https://www.solventum.com